- Home
- HBNC vs GALT Comparison
HBNC vs GALT Comparison
Compare HBNC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBNC | GALT |
|---|---|---|
| Founded | 1873 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 232.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HBNC | GALT |
|---|---|---|
| Price | $18.47 | $6.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $19.67 | $6.00 |
| AVG Volume (30 Days) | 300.9K | ★ 465.8K |
| Earning Date | 01-21-2026 | 11-14-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $51.78 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.91 | N/A |
| 52 Week Low | $12.70 | $0.73 |
| 52 Week High | $18.56 | $6.66 |
Technical Indicators
Market Signals| Indicator | HBNC | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 78.37 | 59.79 |
| Support Level | $16.90 | $5.10 |
| Resistance Level | $18.56 | $6.32 |
| Average True Range (ATR) | 0.41 | 0.54 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 95.59 | 82.05 |
Price Performance
Historical ComparisonAbout HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.